Research Update: GCI Inc. Outlook Revised To Stable; 'BB-' Corporate Credit Rating Affirmed

  • ID: 1785804
  • June 2009
  • Standard & Poors
1 of 3

GCI's operating trends have been healthy the past few quarters, most notably in the consumer segment, where it is increasing penetration across all services. Standard & Poor's revised its outlook on GCI to stable from negative and affirmed its 'BB-' corporate credit rating on the company. The stable outlook reflects our expectation for healthy EBITDA growth over the next year, which should contribute to improved credit protection measures. We expect the company to generate positive discretionary cash flow in the second half of 2009. On June 2, 2009, Standard & Poor's Ratings Services revised the outlook on Anchorage, Alaska-based GCI Inc. to stable from negative. At the same time, we affirmed the ratings on GCI, including the 'BB-' corporate credit...

Companies mentioned in this report are: GCI Inc.
Action: Affirmed
Action: Outlook: Stable

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Product Type: Research Update
Research updates complement media releases. They offer more depth and detail than summary analyses by incorporating all information published in the media release. They are more up to date than summaries in that they are published simultaneously with media releases.

Note: Product cover images may vary from those shown
2 of 3

GCI Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.